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We demonstrated that hydrophobic derivatives of the nonsteroidal anti-inﬂammatory drug (NSAID)ﬂufenamic acid (FA), can be
formed into stable nanometer-sized prodrugs (nanoprodrugs) that inhibit the growth of glioma cells, suggesting their potential
application as anticancer agent. We synthesized highly hydrophobic monomeric and dimeric prodrugs of FA via esteriﬁcation
and prepared nanoprodrugs using spontaneous emulsiﬁcation mechanism. The nanoprodrugs were in the size range of 120 to
140nmandphysicochemicallystableuponlong-termstorageasaqueoussuspension,whichisattributed tothestronghydrophobic
interaction between prodrug molecules. Importantly, despite the highly hydrophobic nature and water insolubility,nanoprodrugs
could be readily activated into the parent drug by porcine liver esterase, presenting a potential new strategy for novel NSAID
prodrug design. The nanoprodrug inhibited the growth of U87-MG glioma cells with IC50 of 20μM, whereas FA showed IC50 of
100μM, suggesting that more eﬃcient drug delivery was achieved with nanoprodrugs.
1.Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are a class
of drugs with analgesic, antipyretic and anti-inﬂammatory
eﬀects and have been widely used in the treatment of pain,
fever, and inﬂammation. NSAIDs exert their anti-inﬂamma-
toryactivity through theinhibition ofcyclooxygenase(COX)
derived prostaglandin synthesis. COX has been recognized
as the ﬁrst enzyme in the formation of prostaglandin (PG)
and thromboxane (TX) from arachidonic acid at the site
of inﬂammation or after infection [1]. COX-1 isozyme is
expressed constitutively in many tissues, whereas COX-2
isozyme is expressed only at the site of inﬂammation [2].
Recent studies have conjectured that elevated expression
of COX-2 has been detected in various cancers, including
colorectal, lung, breast, liver, head and neck, and brain
tumors, whereas COX-1 expression was unaﬀected [3–5].
Several studies have also demonstrated that NSAIDs may be
eﬀective in the prevention and treatment of certain types
of cancers [6–9]. The chemopreventive and antitumori-
genic eﬀects of NSAIDs are believed to be exerted through
the induction of apoptosis followed by inhibition of COX-
2[ 10–13]. Some data also suggest a COX-2-independent
mechanismbecauseapoptosisinductionbyNSAIDsdoesnot
always correlate with their ability to inhibit COX-2 [14–17].
However, the major mechanism by which NSAIDs exert
their anti-inﬂammatory activity, the inhibition of cycloox-
ygenase-derived prostaglandin synthesis, is also responsible
f o rt h ea d v e r s es i d ee ﬀects, such as irritation and ulceration
of the gastrointestinal (GI) mucosa [18]. It is generally
believed that these GI side eﬀects result from the combined
eﬀect of the irritation caused by the free carboxylic groups
in NSAIDsand blockageofprostaglandin biosynthesis in the
GI tract [19].
Prodrug strategy is widely recognized as a potential ap-
proach to overcome toxic side eﬀects that are ascribed to the
irritationcausedbythefreecarboxylicgroupsinNSAIDsand
blockage of prostaglandin biosynthesis in the GI tract. There
have been several attempts to develop prodrugs of NSAIDs
to overcome the adverse side eﬀects as well as to improve
their bioavailability by masking the carboxylic acid groups
through the formation of bioreversible bonds [20–24].2 Journal of Drug Delivery
The development of nanostructured biomaterials with
antitumorigenic eﬃcacy has received signiﬁcant attention
from the pharmaceutical industry, mainly because of their
potential for precise targeting with less severe toxic side
eﬀects. Many eﬀective anticancer therapeutics are low water
soluble and must be in excessive amounts of organic cosol-
vents to obtain a therapeutically eﬀective dose. This limits
clinicalapplicabilityof thesedrugs. The formation intocom-
pact nanostructures obviates the need to use organic sol-
vents, eliminating the interference of toxicside eﬀectscaused
by cosolvents [25, 26]. In addition, by using a nanometer-
sized delivery system, a signiﬁcant drug loading per unit
volumecanbeachieved,which isofcrucialimportance when
high dosing is required.
In our eﬀort tocombine the prodrug conceptand nanos-
tructured drug/drug delivery system we demonstrated that
water-insoluble prodrug compounds can be transformed
into stable nanostructures obviating the need to dissolve the
compounds in organic solvents. In our previous report
we demonstrated six hydrophobic derivatives of NSAIDs
(Figure 1) and their nanoprodrugs [27, 28]. In this study, we
synthesized monomeric and dimeric prodrugs of ﬂufenamic
acid (FA, 2-[(3-triﬂuoromethylphenyl)amino]benzoic acid)
and prepared nanoprodrugs through spontaneous emulsiﬁ-
cation of the prodrugs in acetone. Further, we demonstrated
the antiproliferative eﬀect of FA nanoprodrugs on U87GM
glioma cells.
2.Materialsand Methods
2.1. General Procedures and Materials. Unless otherwise
noted,solventsandchemicalswereobtainedathighestpurity
from Sigma-Aldrich Chemical Co. (St Louis, MO, USA) and
used without further preparation. Chromatographic puriﬁ-
cation of the synthesized compounds was performed using
silica gel (60 ˚ A, 200–400 mesh). The compounds were con-
ﬁrmed by thin layer chromatography (TLC) silicagel plate
(Merck 60 F254). Compounds containing α-lipoic acid were
visualized by treatment with a solution of: 1.5g of KMnO4,
10g of K2CO3, and 1.25mL of 10% NaOH in 200mL of
H2O, followed by gentle heating. The oxidized derivatives
of FA were visualized under UV light. 1Ha n d13CN M R
spectra were conducted on a Varian 400MHz spectrometer
and chemical shifts (δ) were given in ppm relative to TMS.
The spectra were recorded with the solvent CDCl3 at room
temperature.
2.2. High-Performance Liquid Chromatography. HPLC anal-
ysis was performed on a Merck-Hitachi analytical LaChrom
D-7000 HPLC/UV detector system (Merck, Darmstadt, Ger-
many) with a CAPCELL PAK, Type SG 120 (phenom-
enex, Torrance, CA, USA) C18 reversed phase column
(250/4.6mm, 5μm). The separation was performed under
isocratic condition at a ﬂow rate of 1mL/min. The com-
position of the mobile phase (acetonitrile/water mixture
containing 0.1% (v/v) triﬂuoroacetic acid) was adjusted for
prodrugs and their degradation products in order to provide
an appropriate retention time and separation. The detection
was carried out at 254nm.
2.3.SynthesisofFAProdrugs. Thesynthesis andcharacteriza-
tion ofthe monomeric derivative ofα-lipoic acid (ALA)with
tetraethylene glycol (TEG) (ALA-TEG-OH, Scheme 1(a))
was performed as described in [27]. The synthesis and
characterization of the monomeric (Scheme 1(a)) and the
dimeric (Scheme 1(b)) FA derivatives were performed as
follows.
ALA-TEG-OH (3.8mmol) and FA (4.1mmol, FA) in
20mL of anhydrous dichloromethane (DCM) were reacted
with 4-(dimethylamino)-pyridine (DMAP, 4.1mmol) in the
presence of molecular sieve for 10min at room tem-
perature. N-(3-Dimethylaminopropyl)-N-ethylcarbodiim-
ide hydrochloride (EDCI, 4.1mmol) was added portionwise
over 10min and the reaction mixture was stirred for 5h
at room temperature in the dark, ﬁltered, and then con-
centrated under vacuum at room temperature. The prod-
ucts were puriﬁed using column chromatography (100:1
CH3Cl:MeOH) and characterized as described above
(Section 2.1).
For the synthesis of dimeric derivative FA2TEG, FA
(6mmol), and TEG (2.5mmol) in 40mL of anhydrous
DCM were reacted with DMAP (6mmol) in the presence
of molecular sieve for 10min at room temperature. EDCI
(6mmol) was added portionwise over 10min and the
reaction mixture was stirred for 5h at room temperature
in the dark, ﬁltered, and then concentrated under vacuum.
The products were puriﬁed using column chromatography
(100:0.5 CH3Cl:MeOH) and characterized as described
above (Section 2.1).
FA-TEG-OH was synthesized and used for the iden-
tiﬁcation of the degradation products of the monomeric
and dimeric prodrugs during enzymatic hydrolysis. FA
(10mmol) and TEG (30mmol) in 50mL of anhydrous di-
chloromethane (DCM) were reacted with DMAP (15mmol)
in the presence of a molecular sieve (Fluka, 3 ˚ A, 10–20 mesh
beads) for 10min at room temperature. EDCI (10mmol)
was added portionwise over10min and the reaction mixture
was stirred for 5h at room temperature in the dark,
ﬁltered, and then concentrated under vacuum to reduce the
volume. The product FA-TEG-OH and dimeric byproduct
FA2TEG were separated using column chromatography by
loading the concentrated reaction mixture on the column
without prior preparation and characterized as described
above.
FA-TEG-OH. The column chromatography on silica gel
(CHCl3 :MeOH 100:1) gave the compound as a colorless
oil (75%). TLC (CHCl3:MeOH 100:1) Rf 0.33; 1HN M R
(400MHz, CDCl3): δ = 3.51 (t, 2 × H), 3.60 (m, 10 × H),
3.82 (t, 2 × H), 4.42 (t, 2 × H), 6.80 (t, 1 × H), 7.18 (m,
2 × H), 7.40 (m, 4 × H), 8.05 (t, 1 × H), 9.53 (s, 1 × H).
13C NMR (100MHz, CDCl3): δ = 61.66, 63.92, 69.15, 70.27,
70.52, 70.64, 70.68, 72.57, 113.02, 114.31, 117.93, 118.36,
119.49, 124.45, 129.90, 131.61, 131.99, 132.25, 134.31,
141.66, 146.63, 168.21.Journal of Drug Delivery 3
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Figure 1: Nanoprodrugs of NSAIDs. ALA: α-lipoic acid; Ind: indomethacin; Ibu: ibuprofen; Npx: naproxen; TEG: tetraethylene glycol.
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Scheme 1: Synthesis of hydrophobic derivatives of FA.
FA-TEG-ALA. The column chromatography on silica gel
(CHCl3:MeOH 100:1) gave the compound as a yellow
oil (65%). TLC (CHCl3 :MeOH100:1)Rf 0.55; 1HN M R
(400MHz, CDCl3): δ = 1.49 (m, 2 × H), 1.70 (m, 4 ×
H), 1.90 (m, 1 × H), 2.45 (m, 1 × H), 3.10 (m, 2 × H),
3.59 (m, 1 × H), 3.70 (m, 10 × H), 3.82 (t, 2 × H), 4.20
(t, 2 × H), 4.45 (t, 2 × H), 6.80 (t, 1 × H), 7.25 (m,
2 × H), 7.35 (m, 4 × H), 8.07 (t, 1 × H), 9.52 (s, 1 ×
H). 13C NMR (100MHz, CDCl3): δ = 24.61, 28.73, 33.94,
34.59, 38.48, 40.22, 56.34, 63.45, 63.96, 69.17, 70.56, 70.67,
70.75, 113.03, 114.33, 117.97, 118.08, 118.34, 119.52, 124.50,
129.11, 129.91, 131.98, 134.32, 141.69, 146.67, 168.22,
173.44.
FA2TEG. The column chromatography on silica gel
(CHCl3 :MeOH 100:1) gave the compound as a colorless
oil (75%). TLC (CHCl3:MeOH 100:1) Rf 0.75; 1HN M R
(400MHz, CDCl3): δ = 3.65 (m, 8 × H), 3.85 (t, 4 × H),
4.45 (t, 4 × H), 6.80 (t, 1 × H), 7.20 (m, 2 × H), 7.40 (m, 4
× H), 8.00 (t, 1 × H), 9.53 (s, 2 × H). 13C NMR (100MHz,
CDCl3): δ = 63.95, 69.16, 70.72, 70.75, 113.02, 114.31,
117.96, 118.33, 119.51, 122.62, 125.33, 129.89, 131.67,
131.99, 134.31, 141.65, 146.67, 168.22.
2.4. Preparation of FA Nanoprodrugs. Nanoprodrugs were
prepared according to the method using spontaneous
emulsiﬁcation as described [27]. Brieﬂy, 25mg of the FA4 Journal of Drug Delivery
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Figure 2: 1H NMR spectra of (a) FA-TEG-ALA, (b) FA2TEG, and (c) ﬂufenamic acid (FA).
derivatives and 5mg of α-tocopherol were dissolved in ac-
etone (5mL) containing polysorbate 80 (0.1% w/v). The
organic solution was poured under moderate stirring on a
magnetic plate into an aqueous phase prepared by dissolving
25mg of Pluronic F68 in 10mL distilled water (0.25%
w/v). Following 15min of magnetic stirring, the acetone
was removed under reduced pressure at room temperature.
The suspensions were ﬁltered through 0.8μm hydrophilic
syringe ﬁlter (Corning, Part no 431221, Fisher Scientiﬁc
Co., Pittsburgh, PA, USA), dialyzed in cellulose membrane
tube (Sigma, code D9777) overnight in distilled water and
storedat 4◦C.A controlnanosphere was prepared with 25mg
of α-tocopherol in the absence of FA derivatives using the
same procedure as described above. To demonstrate cellular
uptake, nanoprodrugs containing a hydrophobic ﬂuorescent
dye, coumarin 6 (Sigma, code 442631), were prepared using
identical procedure except that 50μg of the dye was added
to the organic FA prodrug solution prior to spontaneous
emulsiﬁcation. The incorporated dye remains associated
with nanoprodrugs during dialysis overnight.
2.5. Size Measurements and Visualization of Nanoprodrugs.
The hydrodynamic size measurement and size distribution
of the nanoprodrugs were performed by the dynamic
light scattering (DLS) using a Coulter N4-Plus Submicron
Particle Sizer (Coulter Corporation, Miami, FL, USA) as
described [27]. For each preparation mean diameter and
mean polydispersity index (PI) of three determinations were
calculated. The error bar (SD) was calculated from tripli-
cate determinations. For visualization of the nanoprodrugs,Journal of Drug Delivery 5
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Figure 3: Size of the nanoprodrugs in the absence (wo Toco) and
presence (w Toco) of α-tocopherol. Light gray bar: monomeric FA-
TEG-ALA; dark gray bar: dimeric FA2TEG.
nanoparticle tracking analysis (NTA) experiments were per-
formedusing a digitalmicroscopeLM10 System(NanoSight,
Amesbury, UK).Asmall amount ofthe dilutednanoprodrug
suspension in water was introduced into the chamber by a
syringe. The particles in the sample were observed using the
digital microscope. The movement of nanoprodrugs under
Brownian motion was analyzed by the NTA, version 1.3
(B196) image analysis software (NanoSight).
2.6. Stability of FA Nanoprodrugs during Long-Term Storage.
The stability of the nanoprodrugs was assessed by measur-
ing the nanoprodrug size and concentrations of prodrug
molecules after 8-week storage at 4◦C.
The size of the nanoprodrugs was measured as described
above (Section 2.5). The amount of intact FA prodrugs
was assessed by RP-HPLC as follows: the suspensions of
nanoprodrugs (100μL) were added to acetonitrile (400μL)
and analyzed using RP-HPLC as described (Section 2.2). The
recovery yield was calculated as follows:
Recovery yield (%)
=
Amount of prodrugs after incubation
Amount of prodrugs before incubation
× 100.
(1)
The error bar (S.D.) was calculated from triplicate determi-
nations.
2.7.EnzymaticHydrolysisofFANanoprodrugs. Thenanopro-
drugs were suspended in phosphate buﬀered saline (PBS,
pH 7.4) and esterase (porcine liver, Sigma, code E3019) was
added to the ﬁnal concentration of 5U/mL. The mixture
was incubated for up to 24h in a water bath at 37◦C.
To determine the amount of enzymatically hydrolyzed spe-
cies of the FA prodrugs, the suspensions of nanoprodrugs
(100μL) were added to acetonitrile (300μL) and analyzed
using RP-HPLC as described in Section 2.2.
2.8. Intracellular Uptake of Fluorescent-Labeled FA Nanopro-
drug in U87 Glioma Cells. To demonstrate intracellular up-
take of the nanoprodrugs, cells were incubated in the
presenceofﬂuorescent-labelednanoprodrugs.Fourchamber
culture slides (BD Biosciences, Bedford, MA) were seeded
with U87 cells, and the cells were allowed to attach for
24h. The medium was replaced with 1.0mL of freshly pre-
pared suspension of the ﬂuorescent-labeled nanoprodrugs
in medium (0.25μg coumarin 6/mL medium), and the
chamberslideswereincubatedfor5h.Toexaminetheuptake
of free dye, cells were incubated in the dye-treated medium.
The dye-treated medium was prepared by incubating the
medium in the presence of dye (0.25μg/mL) for 5h and
sterile ﬁltration. Cells were washed three time with PBS to
remove uninternalized nanoprodrugs, one drop of mount-
ing medium with DAPI (Vectashield, Vector Laboratories,
Burlingame, CA) was added and then cover slide was
placed.Formicroscopicanalysisofintracellularuptakeofthe
ﬂuorescent-labeled nanoprodrugs, a Carl Zeiss Axio Imager
Z1 ﬂuorescence microscope equipped with ApoTome (Carl
Zeiss MicroImaging, Inc., Thornwood, NY, USA) and Leica
DMIRE2 confocal laser-scanning microscope with Confocal
Software (Leica Microsystems, Bannockburn, IL, USA) were
used. For processing and analysis of the images, AxioVision
(Rel. 4.6.3) software (Carl Zeiss) was used. The Carl Zeiss
ﬁlterwith excitation/emissionwavelengthat470/525nmwas
used.
2.9. Cell Counting. U87-MG human glioma cell line was
obtained from American Type Culture Collection (ATCC,
Bethesda, MD, USA). The cells were grown and maintained
as described in [28]. The glioma cells were seeded at
5 × 104 cells per well in 6-well plates containing 2mL
of culture medium and grown for 24h. The cells were
treated with FA nanoprodrugs for 4 days. After treatment,
the culture medium was removed and cells were washed
with PBS. 0.5mL of 0.25% Trypsin/EDTA was added to
each well and the detached cells were counted immediately
in a hemocytometer. The antiproliferative eﬀect of the
nanoprodrugs was presented as a cell number % of control,
which was calculated as follows:
Cell number % of control =

Cell numbertreated
Cell numbercontrol

× 100,
(2)
whereCellnumbertreated isthenumberofcellsaftertreatment
with nanoprodrugs, and Cell numbercontrol is the number of
cells of control culture which was incubated with culture
medium only. The cells were also treated with control
nanosphere prepared from α-tocopherol only. The error bar
(SD) was calculated from triplicate determinations.6 Journal of Drug Delivery
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Figure 4: Image of FA-TEG-ALA nanoprodrug obtained from nanoparticle tracking analysis(NTA) (a, b) and size distribution of FA-TEG-
ALA nanoprodrug as measured by (c) dynamic light scattering (Coulter N4-Plus Submicron Particle Sizer) and (d) NTA. Image (b) is a
magniﬁcation of a part of the image (a).
2.10. Statistical Analysis. The results were analyzed and ex-
pressed as mean ± standard deviation (S.D.). Statistical
analysis of the results was carried out using Student’s t-test.
For all tests, diﬀerences with a P<. 05 were considered to be
signiﬁcant.
3.Resultsand Discussion
3.1. Preparation of Nanoprodrugs of FA. The synthesis of
hydrophobic prodrugs of FA and conversion into nanometer
sized prodrugs (nanoprodrugs) oﬀer several advantages
which are attributed to the speciﬁc characteristics of nanos-
tructures. One of the most remarkable properties of the
nanostructured drug and drug delivery system is that a huge
surface area is created by transformation of bulk materials
into the nanometer-sized. This surface area provides oppor-
tunities for chemical and biological interactions between the
drugs and biological molecules/enzymes in the physiological
environment, leading to an enhanced therapeutic eﬃcacy of
the drugs [29, 30]. These properties of nanostructured bio-
materials have been routinely exploited for the development
of nanostructured prodrugs and drug delivery system.
The increase in hydrophobicity through chemical modi-
ﬁcation isacrucialfactorforthepreparation ofstablenanos-
tructures using spontaneous emulsiﬁcation. This is because
more hydrophobic compounds can be transformed into
more stable nanostructures due to the stronger hydrophobic
interaction between the molecules. The resulting hydropho-
bic nanostructures are stable for a prolonged period of time
in an aqueous biological environment, mainly due to the
insolubilityofthehydrophobicallymodiﬁedcompoundsand
hydrophobic interaction, leading to a strong assembly of the
molecules [14]. The hydrophobicity and compact structure
may reduce the interaction with water, and thus increase the
structural integrity of the nanostructures.Journal of Drug Delivery 7
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F Ab e l o n g st ot h ea c i d i cN S A I D st h a th a v ea n t i - i n -
ﬂammatory properties linked to COX inhibition [31]. This
drug has been reported as an eﬃcient inhibitor of the
chlorinating activity of myeloperoxidase (MPO). MPO is
a heme-containing enzyme of the peroxidase family that
catalyzes the formation of hypochlorous acid (HOCl) in the
presence of hydrogen peroxide (H2O2) and chloride anions
(Cl−) in the complex defense system against exogenous
aggregations [32, 33]. Klabunde et al. showed that FA, along
with several NSAIDs and structurally similar compounds,
strongly inhibited the formation of insoluble transthyretin
(TTR) amyloid ﬁbrils which is known to cause familial
amyloid cardiomyopathy and senile systemic amyloidosis
[34].
ThemonomericderivativeFA-TEG-ALAwassynthesized
using a two-step synthesis as described in Scheme 1(a).
TEG was converted to the mono-ALA derivative ALA-TEG-
OH, which was followed by the esteriﬁcation with FA. The
secondary aromatic amine in FA did not interfere with the
esteriﬁcation. The dimeric derivative of FA was synthesized
using a one-step procedure (Scheme 1(b)).
The structures were conﬁrmed by 1Ha n d13CN M R
spectroscopy. The 1H NMR data indicate that the resulting
spectra are essentially a composite of FA and TEG in the
dimeric derivative and a composite of FA, ALA, and TEG in
the monomeric derivative (Figure 2). The amine proton in
FA is probably involved in a H-bridge with carbonyl oxygen
(C=O )a ss h o w ni nF i g u r e2. This proton peak at 9.5ppm
was not observed in the spectrum of free FA (Figure 2(c)).
The integral of the H-bridged proton was equivalent to
one proton in FA-TEG-ALA, while it was equivalent to two
protons in FA2TEG, reﬂecting the one and two FA in the
FA-TEG-ALA and FA2TEG, respectively. The purity of each
synthesized compound was analyzed by TLC and RP-HPLC.
3.2. Preparation and Characterization of Nanoprodrugs of FA.
The hydrophobic derivatives of FA (Schemes 1(a) and 1(b))
dissolved in acetone spontaneously formed into nanopro-
drugs upon the addition into an aqueous solution con-
taining hydrophilic surfactants by spontaneous emulsiﬁca-
tion process [27, 28, 35–38]. In this study, formulation
parameters were kept the same except for the addition of
α-tocopherol. In the absence of α-tocopherol the size of
the nanoprodrug prepared from the dimeric FA2TEG was
signiﬁcantly smaller than the size the nanoprodrug prepared
from the monomeric FA-TEG-ALA, suggesting that a more
compact spatial arrangement of the symmetrical dimeric
derivative led to the formation of the compacter and smaller
nanoprodrug.
Notably, the retention time of the dimeric FA2TEG in
RP-HPLC was almost twice as much longer than that of the
monomeric FA-TEG-ALA, suggesting a higher hydropho-
bicity of FA2TEG [39, 40]. It can be assumed that the size
decreases with increasing hydrophobicity of the compounds,
probably due to a stronger hydrophobic interaction between
t h em o l e c u l e s .I nt h ep r e s e n c eo fα-tocopherol the size of
the FA-TEG-ALA nanoprodrug became signiﬁcantly smaller
when compared with the size in the absence of α-tocopherol
(Figure 2).Journal of Drug Delivery 9
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Figure 8: Cellular uptake of ﬂuorescent-labeled nanoprodrugs in U87 glioma cells. Cells were incubated with FA-TEG-ALA nanoprodrug
((a)–(c)),FA2TEGnanoprodrug((d)–(f))andindye-treated mediumascontrol((g)–(i)).Leftandmiddlepanelsshowimagesofoverlapped
ﬂuorescence of DAPI and coumarin 6, left with lower and middle with higher magniﬁcation. Right panel shows images of ﬂuorescence of
coumarin 6 only.
Interestingly, practically no diﬀerence in the size was ob-
served for the FA2TEG nanoprodrugs in the absence and
presence of α-tocopherol. This can be explained by the
signiﬁcant increase in the overall hydrophobicity through
the addition of α-tocopherol in the case of FA-TEG-
ALA, whereas it was negligible in the case of FA2TEG,
probably due to the signiﬁcant initial hydrophobicity of
FA2TEG.
In the presence of α-tocopherol the diﬀerence in size be-
tween the FA2TEG and FA-TEG-ALA nanoprodrugs became
smaller, which is especially crucial when the therapeutic
eﬃcacies of the two nanoprodrugs are to be compared.
This is because diﬀerences in the therapeutic eﬃcacy can be
attributed directly to the diﬀerent prodrug molecules in the
nanoprodrugs when the size and other components do not
diﬀer signiﬁcantly from each other. Thus, the nanoprodrugs10 Journal of Drug Delivery
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Figure 9: Eﬀect of nanoprodrug of FA-TEG-ALA (a),nanoprodrug of FA2TEG (b), and free ﬂufenamic acid (c) on the viability of U87-MG
glioma cells.
were prepared in the presence of α-tocopherol for further
experiments.
To give a visualization of the nanoprodrugs, we applied
the nanoparticle tracking and analysis (NTA) technique
which allows direct and real-time visualization of nanopar-
ticles in a liquid as shown in Figures 4(a) and 4(b) [41].
Whereas dynamic light scattering (DLS) is an ensemble
technique that tries to recover a particle size distribution
from the combined signal of all particles present in the
sample, nanoparticle tracking analysis (NTA) investigates
the diﬀusion of individual particles. Thus, DLS calculates
the average particle diameter by measuring ﬂuctuation in
scattering intensity, is highly aﬀected by the presence of a
few large particles, and tends to be weighted to the larger
particles sizes [42]. Indeed, using DLS (Coulter N4-Plus
Submicron Particle Sizer) and NTA for an identical FA-TEG-
ALA nanoprodrug, the average size calculated by DLS was
126nm, which was larger than the size calculated by NTA
(97nm) (Figures 4(c) and 4(d)). The comparison of size
distribution and average size from DLS and NTA indicate
that few larger nanoprodrugs (>300nm) have signiﬁcant
inﬂuence on the size calculation in DLS.
The stability of the nanoprodrugs was assessed by
measuring the size and contents of the intact FA prodrug
molecules after 8-week storage at 4◦C. In this study, the size
ofthe nanoprodrugs remained almost unchanged (Figure5),
and the recovery yield of the prodrugs was 75% and 90%
for the FA-TEG-ALA and FA2TEG, respectively. It is believed
that the nanoprodrugs from the more hydrophobic FA2TEG
formed more stable and compact nanostructures, which
can be ascribed to the stronger hydrophobic assembly of
FA2TEG. This may reduce the interaction with water, and
consequently decrease hydrolytic degradation and increase
the structural integrity of the nanoprodrug.
3.3. Enzymatic Hydrolysis of FA Nanoprodrugs. In order to
assess the enzymatic prodrug activation from the nanopro-
drugs, the rate of enzymatic reconversion of the prodrugs
into FA and other degradation products was investigated in
vitro with porcine liver esterase. As shown in Figure 6(a),
FA-TEG-ALA nanoprodrug was activated nearly completely
after 5h of incubation at 37◦C, whereas no activation
was observed in the FA2TEG nanoprodrug during the
same period of time. This can be attributed to the moreJournal of Drug Delivery 11
hydrophobic nature of the dimeric FA2TEG prodrug which
makes the interaction between the molecules and enzymes
more diﬃcult. In addition, FA is bulkier than ALA, which
may increase the steric hindrance towards the enzymes [43,
44]. This assumption was conﬁrmed by the observation that
the ALA was ﬁrst hydrolyzed from FA-TEG-ALA followed by
the breakdown of FA-TEG-OH to FA and TEG (Figures 6(c)
and 7).
3.4. Intracellular Uptake of Fluorescent-Labeled FA Nanopro-
drug in U87 Glioma Cells. In order to demonstrate the
cellular uptake of nanoprodrugs, we prepared ﬂuorescent-
labeled nanoprodrugs with the hydrophobic dye, coumarin
6. Due to the hydrophobic nature, the dye remained
associated with the nanoprodrugs after overnight dialysis
and even after the incubation in PBS buﬀer and cell culture
medium [45]. Confocal laser scanning microscopy of U87
glioma cells treated with ﬂuorescent-labeled nanoprodrugs
showed strong internalization of the nanoprodrugs within
5hofincubation.BothnanoprodrugsFA-TEG-ALA(Figures
8(a)–8(c))a n dF A 2TEG (Figures 8(d)–8(f)) showed similar
cellular uptake, whereas cells incubated in the dye-treated
control medium did not show any detectable ﬂuorescence
(Figures 8(g)–8(i)).
Some cells showed a stronger accumulation along the
membrane area, while other showed more evenly distributed
pattern in the cytoplasm. Interestingly, cells contained
numeroustinyvesiclesthat weredispersedinthecytoplasmic
compartment. The vesicles are probably endosomal vesicles
(endosomes), suggesting that the cellular uptake occurs via
endocytosis. Considering the diﬀerent spatial intensity and
localization of the ﬂuorescent signals within the cells, it can
beconcludedthatafter endocytosisthenanoprodrugs escape
from the endosomes to the cytoplasm and are dispersed
evenly throughout the cytoplasm.
3.5. Eﬀect of FA Nanoprodrug on Cell Proliferation. In order
to evaluate the eﬀect of FA nanoprodrugs on tumor cell
growth, we studied the eﬀect on the cell growth of U87-
MG glioma cells. Glioma cells were treated with nanopro-
drugs from FA-TEG-ALA and FA2TEG, and also with FA
in the concentration range of 10 to 200μM. Cells were
also treated with control nanospheres prepared from α-
tocopherol only by exposure to an equimolar concentration
of α-tocopherol. As shown in Figure 6, the nanoprodrug of
FA-TEG-ALA completely inhibited the cell proliferation at
the concentration of 50μM, whereas the nanoprodrug of
FA2TEG inhibited only 30% at the highest concentration
of 200μM. These results were well expected because the
prodrug FA2TEG was almost inert towards chemical and
enzymatic hydrolysis (Sections 3.2 and 3.3). Based on the
results of this study, the stability and biodegradability of the
nanoprodrugs may be adjusted to meet the needs for diverse
practicalapplicationsviamodiﬁcationofprodrugstructures.
Interestingly, the inhibitory eﬀect of the nanoprodrug FA-
TEG-ALAwas muchhigher than thatof theFA(Figure9(c)),
suggesting the existence of more eﬃcient cellular delivery
mechanism for the nanoprodrug.
4.Conclusion
In this study we showed that hydrophobic derivative of
FA can be formed into stable nanoprodrug that is readily
activated by hydrolytic enzyme and inhibits the growth of
malignant cells, suggesting their potential application as
anticancer agents. Nanoprodrugs of FA were prepared by
spontaneous emulsiﬁcation of the monomeric prodrug FA-
TEG-ALA and dimeric FA2TEG, and their antiproliferative
eﬀects were demonstrated using U87-MG glioma cells. The
nanoprodrug from FA-TEG-ALA inhibited the cell growth
signiﬁcantly and induced cell death, whereas the nanopro-
drug from FA2TEG did not show any comparable eﬀect on
cellgrowthandviability.Wedemonstratedusingﬂuorescent-
labeded nanoprodrugs that both nanoprodrugs FA-TEG-
ALA and FA2TEG showed similar cellular uptake.Obviously,
themore potenteﬀectofthemonomeric nanoprodrugisdue
to the higher parent drug concentration which is ascribed to
the higher enzymatic activation. In addition, the FA-TEG-
ALAnanoprodruginhibitedcellgrowthmoreeﬃcientlythan
free FA, suggesting a delivery mechanism speciﬁc to the
nanoprodrug.Wearecurrentlyinvestigatingthemechanisms
of the cellular uptake and the molecular eventsleading to the
antiproliferative eﬀect of the FA nanoprodrug.
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